Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa

  1. Liyun Zhang
  2. Conan Chen
  3. Jie Fu
  4. Brendan Lilley
  5. Cynthia Berlinicke
  6. Baranda Hansen
  7. Ding Ding
  8. Guohua Wang
  9. Tao Wang
  10. Daniel Shou
  11. Ying Ye
  12. Timothy Mulligan
  13. Kevin Emmerich
  14. Meera T Saxena
  15. Kelsi R Hall
  16. Abigail V Sharrock
  17. Carlene Brandon
  18. Hyejin Park
  19. Tae-In Kam
  20. Valina L Dawson
  21. Ted M Dawson
  22. Joong Sup Shim
  23. Justin Hanes
  24. Hongkai Ji
  25. Jun O Liu
  26. Jiang Qian
  27. David F Ackerley
  28. Baerbel Rohrer
  29. Donald J Zack
  30. Jeff S Mumm  Is a corresponding author
  1. Johns Hopkins University, United States
  2. Johns Hopkins University School of Public Health, United States
  3. Johns Hopkins University School of Medicine, United States
  4. Victoria University of Wellington, New Zealand
  5. Medical University of South Carolina, United States
  6. University of Macau, Macao

Abstract

Retinitis pigmentosa (RP) and associated inherited retinal diseases (IRDs) are caused by rod photoreceptor degeneration, necessitating therapeutics promoting rod photoreceptor survival. To address this, we tested compounds for neuroprotective effects in multiple zebrafish and mouse RP models, reasoning drugs effective across species and/or independent of disease mutation may translate better clinically. We first performed a large-scale phenotypic drug screen for compounds promoting rod cell survival in a larval zebrafish model of inducible RP. We tested 2,934 compounds, mostly human-approved drugs, across six concentrations, resulting in 113 compounds being identified as hits. Secondary tests of 42 high-priority hits confirmed eleven lead candidates. Leads were then evaluated in a series of mouse RP models in an effort to identify compounds effective across species and RP models, i.e., potential pan-disease therapeutics. Nine of eleven leads exhibited neuroprotective effects in mouse primary photoreceptor cultures, and three promoted photoreceptor survival in mouse rd1 retinal explants. Both shared and complementary mechanisms of action were implicated across leads. Shared target tests implicated parp1-dependent cell death in our zebrafish RP model. Complementation tests revealed enhanced and additive/synergistic neuroprotective effects of paired drug combinations in mouse photoreceptor cultures and zebrafish, respectively. These results highlight the value of cross-species/multi-model phenotypic drug discovery and suggest combinatorial drug therapies may provide enhanced therapeutic benefits for RP patients.

Data availability

Source data files have been uploaded

The following previously published data sets were used

Article and author information

Author details

  1. Liyun Zhang

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    Liyun Zhang, has filed a provisional patent for the discoveries described herein..
  2. Conan Chen

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  3. Jie Fu

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  4. Brendan Lilley

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  5. Cynthia Berlinicke

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  6. Baranda Hansen

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  7. Ding Ding

    Department of Biostatistics, Johns Hopkins University School of Public Health, Baltimore, United States
    Competing interests
    No competing interests declared.
  8. Guohua Wang

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  9. Tao Wang

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  10. Daniel Shou

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  11. Ying Ye

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  12. Timothy Mulligan

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  13. Kevin Emmerich

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  14. Meera T Saxena

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  15. Kelsi R Hall

    Victoria University of Wellington, Wellington, New Zealand
    Competing interests
    No competing interests declared.
  16. Abigail V Sharrock

    Victoria University of Wellington, Wellington, New Zealand
    Competing interests
    No competing interests declared.
  17. Carlene Brandon

    Ophthalmology, Medical University of South Carolina, Charleston, United States
    Competing interests
    No competing interests declared.
  18. Hyejin Park

    School of Biological Science, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  19. Tae-In Kam

    School of Biological Science, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  20. Valina L Dawson

    School of Biological Science, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2915-3970
  21. Ted M Dawson

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6459-0893
  22. Joong Sup Shim

    Faculty of Health Sciences, University of Macau, Taipa, Macao
    Competing interests
    No competing interests declared.
  23. Justin Hanes

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  24. Hongkai Ji

    Department of Biostatistics, Johns Hopkins University School of Public Health, Baltimore, United States
    Competing interests
    No competing interests declared.
  25. Jun O Liu

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3842-9841
  26. Jiang Qian

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  27. David F Ackerley

    Victoria University of Wellington, Wellington, New Zealand
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6188-9902
  28. Baerbel Rohrer

    Ophthalmology, Medical University of South Carolina, Charleston, United States
    Competing interests
    No competing interests declared.
  29. Donald J Zack

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  30. Jeff S Mumm

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    For correspondence
    jmumm3@jhmi.edu
    Competing interests
    Jeff S Mumm, holds patents for the NTR inducible cell ablation system (US #7,514,595) and uses thereof (US #8,071,838 and US#8431768). Has filed a provisional patent for the discoveries described herein. All other authors have no commercial relationships..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2575-287X

Funding

Foundation Fighting Blindness (Wynn-Gund TRAP)

  • Jeff S Mumm

National Institutes of Health (P30EY001765)

  • Donald J Zack

National Institutes of Health (R01EY019320)

  • Baerbel Rohrer

Department of Veterans Affairs (RX000444 and BX003050)

  • Baerbel Rohrer

South Carolina SmartState Endowment

  • Baerbel Rohrer

Flight Attendant Medical Research Institute

  • Jun O Liu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal studies described herein were performed in accordance with both the Association for Research in Vision and Ophthalmology (ARVO) statement on the "Use of Animals in Ophthalmic and Vision Research" and the National Institutes of Health (NIH) Office of Laboratory Animal Welfare (OLAW) policies regarding studies conducted in vertebrate species. Animal protocols were approved by the Animal Care and Use Committees of the Johns Hopkins University School of Medicine (protocol # FI19M489 and #MO20M253) and Medical University of South Carolina (protocol #2018-00399).

Copyright

© 2021, Zhang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,165
    views
  • 422
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Liyun Zhang
  2. Conan Chen
  3. Jie Fu
  4. Brendan Lilley
  5. Cynthia Berlinicke
  6. Baranda Hansen
  7. Ding Ding
  8. Guohua Wang
  9. Tao Wang
  10. Daniel Shou
  11. Ying Ye
  12. Timothy Mulligan
  13. Kevin Emmerich
  14. Meera T Saxena
  15. Kelsi R Hall
  16. Abigail V Sharrock
  17. Carlene Brandon
  18. Hyejin Park
  19. Tae-In Kam
  20. Valina L Dawson
  21. Ted M Dawson
  22. Joong Sup Shim
  23. Justin Hanes
  24. Hongkai Ji
  25. Jun O Liu
  26. Jiang Qian
  27. David F Ackerley
  28. Baerbel Rohrer
  29. Donald J Zack
  30. Jeff S Mumm
(2021)
Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa
eLife 10:e57245.
https://doi.org/10.7554/eLife.57245

Share this article

https://doi.org/10.7554/eLife.57245

Further reading

    1. Cell Biology
    2. Developmental Biology
    Dilara N Anbarci, Jennifer McKey ... Blanche Capel
    Research Article

    The rete ovarii (RO) is an appendage of the ovary that has been given little attention. Although the RO appears in drawings of the ovary in early versions of Gray’s Anatomy, it disappeared from recent textbooks, and is often dismissed as a functionless vestige in the adult ovary. Using PAX8 immunostaining and confocal microscopy, we characterized the fetal development of the RO in the context of the mouse ovary. The RO consists of three distinct regions that persist in adult life, the intraovarian rete (IOR), the extraovarian rete (EOR), and the connecting rete (CR). While the cells of the IOR appear to form solid cords within the ovary, the EOR rapidly develops into a convoluted tubular epithelium ending in a distal dilated tip. Cells of the EOR are ciliated and exhibit cellular trafficking capabilities. The CR, connecting the EOR to the IOR, gradually acquires tubular epithelial characteristics by birth. Using microinjections into the distal dilated tip of the EOR, we found that luminal contents flow toward the ovary. Mass spectrometry revealed that the EOR lumen contains secreted proteins potentially important for ovarian function. We show that the cells of the EOR are closely associated with vasculature and macrophages, and are contacted by neuronal projections, consistent with a role as a sensory appendage of the ovary. The direct proximity of the RO to the ovary and its integration with the extraovarian landscape suggest that it plays an important role in ovary development and homeostasis.

    1. Cell Biology
    2. Developmental Biology
    Yan Zhang, Hua Zhang
    Insight

    Long thought to have little relevance to ovarian physiology, the rete ovarii may have a role in follicular dynamics and reproductive health.